Prescribing information

 

_

REVOLADE CAN GIVE CONFIDENCE THROUGH CONSISTENT RESPONSE IN ITP PATIENTS1,2*

REVOLADE achieved a continuous platelet response in the long-term study EXTEND:1

  • 51% of patients (n=126/248) responded* for at least 31 consecutive weeks
  • 20% of patients had a response at every assessment for 2 years

Median treatment exposure was 2.37 years (range, 2 days to 8.76 years).1 After 250 weeks of treatment, 15 of the original 302 patients were still on REVOLADE.1

The EXTEND Study was designed to investigate the long-term response* and safety of REVOLADE in ITP patients for up to 7 years.1

In total, 302 patients enrolled onto this study, where 259 (85.8%) achieved a response* and 133 (52%) of 257 patients achieved a continuous response* of 25 weeks or longer.1

Icon of person depicting the ITP patient response rate to REVOLADE in EXTEND

 

REVOLADE CAN GIVE CONFIDENCE THROUGH DURABLE PLATELET RESPONSE1-3

REVOLADE was associated with increased platelet counts over a 7-year study period.1

  • Median platelet counts were maintained at platelet concentrations over 50,000/μL for over 4.5 years
  • After 250 weeks of treatment, 15 of the original 302 patients were still on REVOLADE

*Response: platelet count higher than 50,000/μL at least once in the absence of rescue therapy. To qualify for the prior studies, patients must have had ITP for at least 6 months, insufficient response to at least 1 previous ITP treatment, and a baseline platelet count lower than 30,000/μL.

Abbreviation: ITP, immune thrombocytopenia.

References

  1. Wong RSM, et al. Blood. 2017;130(23):2527–2536.
  2. Data on file REVDOF001.
  3. REVOLADE Summary of Product Characteristics.
HCP19-C002c(1) June 2020.

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/7819/smpc

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]